Concomitant Imaging Dose and Cancer Risk in Image Guided Thoracic Radiation Therapy

Recommendation for reducing the crystalline lens exposure dose by reducing imaging field width in cone-beam computed tomography for image-guided radiation therapy: an anthropomorphic phantom study

In cone-beam computed tomography (CBCT) for image-guided radiation therapy (IGRT) of the head, we evaluated the exposure dose reduction effect to the crystalline lens and position-matching accuracy by narrowing one side (X2) of the X-ray aperture (blade) in the X-direction. We defined the ocular surface dose of the head phantom as the crystalline lens exposure dose and measured using a radiophotoluminescence dosimeter (RPLD, GD-352 M) in the preset field (13.6 cm) and in each of the fields when blade X2 aperture was reduced in 0.5 cm increments from 10.0 to 5.0 cm. Auto-bone matching was performed on CBCT images acquired five times with blade X2 aperture set to 13.6 cm and 5.0 cm at each position when the head phantom was moved from - 5.0 to + 5.0 mm in 1.0 mm increment. The maximum reduction rate in the crystalline lens exposure dose was - 38.7% for the right lens and - 13.2% for the left lens when blade X2 aperture was 5.0 cm. The maximum difference in the amount of position correction between blade X2 aperture of 13.6 cm and 5.0 cm was 1 mm, and the accuracy of auto-bone matching was similar. In CBCT of the head, reduced blade X2 aperture is a useful technique for reducing the crystalline lens exposure dose while ensuring the accuracy of position matching.

A generalizable new figure of merit for dose optimization in dual energy cone beam CT scanning protocols

Objective. This study proposes and evaluates a new figure of merit (FOMn) for dose optimization of Dual-energy cone-beam CT (DE-CBCT) scanning protocols based on size-dependent modeling of radiation dose and multi-scale image quality.Approach. FOMn was defined using Z-score normalization and was proportional to the dose efficiency providing better multi-scale image quality, including comprehensive contrast-to-noise ratio (CCNR) and electron density (CED) for CatPhan604 inserts of various materials. Acrylic annuluses were combined with CatPhan604 to create four phantom sizes (diameters of the long axis are 200 mm, 270 mm, 350 mm, and 380 mm, respectively). DE-CBCT was decomposed using image-domain iterative methods based on Varian kV-CBCT images acquired using 25 protocols (100 kVp and 140 kVp combined with 5 tube currents).Main results. The accuracy of CED was approximately 1% for all protocols, but degraded monotonically with the increased phantom sizes. Combinations of lower voltage + higher current and higher voltage + lower current were optimal protocols balancing CCNR and dose. The most dose-efficient protocols for CED and CCNR were inconsistent, underlining the necessity of including multi-scale image quality in the evaluation and optimization of DE-CBCT. Pediatric and adult anthropomorphic phantom tests confirmed dose-efficiency of FOMn-recommended protocols.Significance. FOMn is a comprehensive metric that collectively evaluates radiation dose and multi-scale image quality for DE-CBCT. The models and data can also serve as lookup tables, suggesting personalized dose-efficient protocols for specific clinical imaging purposes.

Radiotherapy respiratory motion management in hepatobiliary and pancreatic malignancies: a systematic review of patient factors influencing effectiveness of motion reduction with abdominal compression

BACKGROUND

The effectiveness of abdominal compression for motion management in hepatobiliary-pancreatic (HPB) radiotherapy has not been systematically evaluated.

METHODS & MATERIALS

A systematic review was carried out using PubMed/Medline, Cochrane Library, Web of Science, and CINAHL databases up to 1 July 2021. No date restrictions were applied. Additional searches were carried out using the University of Manchester digital library, Google Scholar and of retrieved papers' reference lists. Studies conducted evaluating respiratory motion utilising imaging with and without abdominal compression in the same patients available in English were included. Studies conducted in healthy volunteers or majority non-HPB sites, not providing descriptive motion statistics or patient characteristics before and after compression in the same patients or published without peer-review were excluded. A narrative synthesis was employed by tabulating retrieved studies and organising chronologically by abdominal compression device type to help identify patterns in the evidence.

RESULTS

The inclusion criteria were met by 6 studies with a total of 152 patients. Designs were a mix of retrospective and prospective quantitative designs with chronological, non-randomised recruitment. Abdominal compression reduced craniocaudal respiratory motion in the majority of patients, although in four studies there were increases seen in at least one direction. The influence of patient comorbidities on effectiveness of compression, and/or comfort with compression was not evaluated in any study.

CONCLUSION

Abdominal compression may not be appropriate for all patients, and benefit should be weighed with potential increase in motion or discomfort in patients with small initial motion (<5 mm). Patient factors including male sex, and high body mass index (BMI) were found to impact the effectiveness of compression, however with limited evidence. High-quality studies are warranted to fully assess the clinical impact of abdominal compression on treatment outcomes and toxicity prospective in comparison to other motion management strategies.

Examining the frequency and concomitant dose of geometric verification imaging for patients undergoing proton beam therapy for ocular tumours; an audit of current clinical practice

OBJECTIVES

This paper uses clinical audit to determine the extent and dosimetric impact of additional imaging for patients undergoing ocular proton beam therapy who have no clips visible in the collimated beam.

METHODS

An audit was conducted on 399 patients treated at The National Centre for Eye Proton Therapy between 3 July 2017 and 14 June 2019. The mean total number of image pairs over the course of treatment for patients with and without clips visible in the collimated beam were compared.

RESULTS

Among 364 evaluable patients, 333 had clips visible in the collimated beam and 31 did not. There was a statistically significant increase of five image pairs required for patients with no clips visible compared with those with clips visible (mean 14.6 vs 9.6 image pairs, respectively; p = 2.74 × 10-6). This equated to an additional 1.5 mGy absorbed dose, representing an increase in secondary cancer induction risk from 0.0004 to 0.0007%.

CONCLUSIONS

The small increase in concomitant dose and set-up time for patients with no clips visible in the collimated beam is not clinically significant.

ADVANCES IN KNOWLEDGE

This novel work highlights clinical audit from real on-treatment geometric verification data and frequencies, rather than protocols, for ocular proton beam therapy; something not present in the literature. The simple and straightforward methodology is easily and equally applicable to clinical audits (especially those under Ionising Radiation (Medical Exposure) Regulations) for photon techniques.

Evaluation of IGRT-Induced Imaging Doses and Secondary Cancer Risk for SBRT Early Lung Cancer Patients In Silico Study

OBJECTIVES

This study performed dosimetry studies and secondary cancer risk assessments on using electronic portal imaging device (EPID) and cone beam computed tomography (CBCT) as image guided tools for the early lung cancer patients treated with SBRT.

METHODS

The imaging doses from MV-EPID and kV-CBCT of the Edge accelerator were retrospectively added to sixty-one SBRT treatment plans of early lung cancer patients. The MV-EPID imaging dose (6MV Photon beam) was calculated in Pinnacle TPS, and the kV-CBCT imaging dose was simulated and calculated by modeling of the kV energy beam in TPS using Pinnacle automatic modeling program. Three types of plans, namely PlanEPID, PlanCBCT and Planorigin, were generated with incorporating doses of EPID, CBCT and no imaging, respectively, for analysis. The effects of imaging doses on dose-volume-histogram (DVH) and plan quality were analyzed, and the excess absolute risk (EAR) of secondary cancer for ipsilateral lung was evaluated.

RESULTS

The regions that received less than 50 cGy were significantly impacted by the imaging doses, while the isodose lines greater than 1000 cGy were barely changed. The DVH values of ipsilateral lung increased the most in PlanEPID, followed by PlanCBCT. Compared to Planorigin on the average, the estimated EAR of ipsilateral lung in PlanEPID increased by 3.43%, while the corresponding EAR increase in PlanCBCT was much smaller (about 0.4%). Considering only the contribution of the imaging dose, the EAR values for the ipsilateral lung due to the MV-EPID dose in 5 years,10 years and 15 years were 1.49 cases, 2.09 cases and 2.88 cases per 104PY respectively, and those due to the kV-CBCT dose were about 9 times lower, correspondingly.

CONCLUSIONS

The imaging doses produced by MV-EPID and kV-CBCT had little effects on the target dose coverage. The secondary cancer risk caused by MV-EPID dose is more than 8.5 times that of kV-CBCT.

Estimation of effective imaging dose and excess absolute risk of secondary cancer incidence for four-dimensional cone-beam computed tomography acquisition

This study was conducted to estimate the organ equivalent dose and effective imaging dose for four-dimensional cone-beam computed tomography (4D-CBCT) using a Monte Carlo simulation, and to evaluate the excess absolute risk (EAR) of secondary cancer incidence. The EGSnrc/BEAMnrc were used to simulate the on-board imager (OBI) from the TrueBeam linear accelerator. Specifically, the OBI was modeled based on the percent depth dose and the off-center ratio was measured using a three-dimensional (3D) water phantom. For clinical cases, 15 lung and liver cancer patients were simulated using the EGSnrc/DOSXYZnrc. The mean absorbed doses to the lung, stomach, bone marrow, esophagus, liver, thyroid, bone surface, skin, adrenal glands, gallbladder, heart, intestine, kidney, pancreas and spleen, were quantified using a treatment planning system, and the equivalent doses to each organ were calculated. Subsequently, the effective dose was calculated as the weighted sum of the equivalent dose, and the EAR of the secondary cancer incidence was determined for each organ with the use of the biologic effects of ionizing radiation (BEIR) VII model. The effective doses were 3.9 ± 0.5, 15.7 ± 2.0, and 7.3 ± 0.9 mSv, for the lung, and 4.2 ± 0.6, 16.7 ± 2.4, and 7.8 ± 1.1 mSv, for the liver in the respective cases of the 3D-CBCT (thorax, pelvis) and 4D-CBCT modes. The lung EARs for males and females were 7.3 and 10.7 cases per million person-years, whereas the liver EARs were 9.9 and 4.5 cases per million person-years. The EAR increased with increasing time since radiation exposure. In clinical studies, we should use 4D-CBCT based on consideration of the effective dose and EAR of secondary cancer incidence.

Pediatric cone beam CT on Varian Halcyon and TrueBeam radiotherapy systems: radiation dose and positioning accuracy evaluations

Medical exposure to ionizing irradiation has become a recognised carcinogenic risk. Balancing the concomitant imaging dose and positioning accuracy is critical in image-guided-radiotherapy (IGRT) especially for children, whose higher biological susceptibility and longer expected life make them more vulnerable to develop secondary cancer. This work aims to evaluate and benchmark the imaging dose and positioning accuracy of a new MV cone-beam-CT (CBCT)-guided IGRT system, Varian Halcyon, against conventional kV CBCT. Weighted-CT-dose-index (CTDI_w) were measured for Varian TrueBeam kV CBCT, and computed for Halcyon MV CBCT using Eclipse system as validated before. Simulating the IGRT workflow, the positioning accuracy of correcting a known shift was tested on various regions of 1-year, 5-year and adult anthropomorphic phantoms, respectively. Inter-scanner and inter-protocol comparisons of dose and accuracy were performed. kV CTDI_w for 'Head', 'Thorax', 'Pelvis' and 'Image Gently' (in CTDI_Φ16cm/CTDI_Φ32cm phantoms, respectively) protocols were measured as 4.5 mGy, 5.4 mGy, 19.3 mGy, and 1.1 mGy/0.5 mGy, respectively. Using 'High Quality' mode, MV CTDI_w in the CTDI_Φ16cm and CTDI _Φ32cm phantoms were computed as 84.5 mGy and 63.8 mGy (imaging length = 28 cm), 68.8 mGy and 55.5 mGy (imaging length = 16 cm), respectively, which were about twice of 'Low Dose' mode. The maximum positioning deviation observed on Halcyon was 0.51 mm ('Low Dose' adult thorax), which was lower than that of standard (0.58 mm, 'Pelvis' adult pelvis) and 'Image Gently' kV CBCT (1.57 mm, adult pelvis). Accuracy of 'Image Gently' kV CBCT head & neck and thoracic imaging were clinically acceptable for adults (maximum deviation = 0.54 mm, adult thorax). Complying with Image Gently campaign, dose-efficient protocols should be used for pediatric IGRT, achieving comparable positioning accuracy on the new Halcyon MV CBCT system relative to the conventional kV CBCT.

Dose calculation deviations induced by fractional image-guided-couch-shifts for Varian Halcyon MV cone beam CT

PURPOSE

To assess the criticality of calculation deviations induced by fractional image-guided-couch-shifts for Halcyon MV cone beam CT (CBCT) dose, which is incorporated as part of total treatment dose.

METHODS

Eclipse-calculated imaging dose was first validated in 'Cheese Phantom' by measurement. Then, the actual imaging dose (D_act) for 18 historical patients of various sites were recalculated based on 513 MV CBCT-guided-couch-shift data, and compared with reference computations based on treatment isocentre (D_ref). Patient- and plan-specific dose from treatment fields was integrated with D_act and D_ref respectively for comparison.

RESULTS

The average absolute relative disagreements between the measured and calculated dose were less than 1.23%. The mean ± 1SD of gamma passing rates of the accumulated imaging dose and total dose were 80.71 ± 6.22% and 99.81 ± 0.32% respectively based on 3 mm/3%/local/10% threshold criteria. The accumulated errors of minimum imaging dose to PTV were no larger than -14.38 cGy, which were reduced to -0.82 cGy after the heterogeneous treatment dose was overlaid. The mean relative discrepancies of PTV minimum dose were -0.61 cGy (-0.71%) and -0.00 (0.00%), before and after incorporating the treatment dose respectively.

CONCLUSIONS

The Eclipse-calculated Halcyon MV CBCT dose was validated. Although the isocentre displacement-induced imaging dose calculation errors for Halcyon MV CBCT were partially cancelled out by couch shifts of various directions and distances, especially after the incorporation of heterogeneous treatment dose, it was still advisable to monitor the accumulated deviations and replan when unacceptable target under-dose or organ over-dose were observed.

A multicenter dosimetry study to evaluate the imaging dose from Elekta XVI and Varian OBI kV-CBCT systems to cardiovascular implantable electronic devices (CIEDs)

The increasing use of daily CBCT in radiotherapy has raised concerns about the additional dose delivered to the patient, and it can also become a concern issue for those patients with cardiovascular implantable electronic devices (CIEDs) (Pacemaker [PM] and Implantable Cardioverter Defibrillator [ICD]). Although guidelines highly recommend that the cumulative dose received by CIEDs should be kept as low as possible, and a safe threshold based on patient risk classification needs to be respected, this additional imaging dose is not usually considered. Four centers with different dosimetry systems and different CBCT imaging protocols participated in this multicenter study to investigate the imaging dose to the CIEDs from Elekta XVI and Varian OBI kV-CBCT systems. It was found that although imaging doses received by CIEDs outside the CBCT field are negligible, special attention should be paid to this value when CIEDs are inside the field because the daily use of CBCT can sometimes contribute considerably to the total dose received by a CIED.

Imaging dose and secondary cancer risk in image-guided radiotherapy of pediatric patients

BACKGROUND

Daily image-guided radiotherapy (IGRT) can contribute to cover extended body volumes with low radiation dose. The effect of additional imaging dose on secondary cancer development is modelled for a collective of children with Morbus Hodgkin.

METHODS

Eleven radiotherapy treatment plans from pediatric patients with Hodgkin's lymphoma were retrospectively analyzed, including imaging dose from scenarios using different energies (kV/MV) and planar/cone-beam computed tomography (CBCT) techniques. In addition to assessing the effect of imaging dose on organs at risk, the excess average risk (EAR) for developing a secondary carcinoma of the lung or breast was modelled.

RESULTS

Although the variability between the patients is relatively large due to the different target volumes, the additional EAR due to imaging can be consistently determined. For daily 6MV CBCT, the EAR for developing a secondary cancer at age 50 is over 3 cases per 104 PY (patient-years) for the female breast and 0.7-0.8 per 104 PY for the lungs. This can be decreased by using only planar images (< 1 per 104 PY for the breast and 0.1 for the lungs). Similar values are achieved by daily 360° kV CBCT (0.44-0.57 per 104 PY for the breast and 0.08 per 104 PY for the lungs), which is again reduced for daily 200° kV CBCT (0.02 per 104 PY for the lungs and 0.07-0.08 per 104 PY for the breast). These values increase if an older attained age is considered (e.g., for 70 years, by a factor of four for the lungs).

CONCLUSIONS

Daily imaging can be performed with an additional secondary cancer risk of less than 1 per 104 PY if kV CBCT is applied. If MV modalities must be chosen, a similar EAR can be achieved with planar images. A further reduction in risk is possible if the imaging geometry allows for sparing of the breast by a partial rotation underneath the patient.

Imaging Dose, Cancer Risk and Cost Analysis in Image-guided Radiotherapy of Cancers

The purpose of this retrospective study is to evaluate the cumulative imaging doses, the associated cancer risk and the cost related to the various radiological imaging procedures in image-guided radiotherapy of cancers. Correlations between patients’ size and Monte Carlo simulated organ doses were established and validated for various imaging procedures, and then used for patient-specific organ dose estimation of 4,832 cancer patients. The associated cancer risk was estimated with published models and the cost was calculated based on the standard billing codes. The average (range) cumulative imaging doses to the brain, lungs and red bone marrow were 38.0 (0.5–177.3), 18.8 (0.4–246.5), and 49.1 (0.4–274.4) cGy, respectively. The associated average (range) lifetime attributable risk of cancer incidence per 100,000 persons was 78 (0–2798), 271 (1–8948), and 510 (0–4487) for brain cancer, lung cancer and leukemia, respectively. The median (range) imaging cost was $5256 (4268–15896) for the head scans, $5180 (4268–16274) for the thorax scans, and $7080 (4268–15288) for the pelvic scans, respectively. The image-guidance procedures and the accumulated imaging doses should be incorporated into clinical decision-making to personalize radiotherapy for individual patients.

Estimation of patient-specific imaging dose for real-time tumour monitoring in lung patients during respiratory-gated radiotherapy

PURPOSE

To quantify the patient-specific imaging dose for real-time tumour monitoring in the lung during respiratory-gated stereotactic body radiotherapy (SBRT) in clinical cases using SyncTraX.

METHODS AND MATERIALS

Ten patients who underwent respiratory-gated SBRT with SyncTraX were enrolled in this study. The imaging procedure for real-time tumour monitoring using SyncTraX was simulated using Monte Carlo. We evaluated the dosimetric effect of a real-time tumour monitoring in a critical organ at risk (OAR) and the planning target volume (PTV) over the course of treatment. The relationship between skin dose and gating efficiency was also investigated.

RESULTS

For all patients, the mean D50 to the PTV, ipsilateral lung, liver, heart, spinal cord and skin was 118.3 (21.5-175.9), 31.9 (9.5-75.4), 15.4 (1.1-31.6), 10.1 (1.3-18.1), 25.0 (1.6-101.8), and 3.6 (0.9-7.1) mGy, respectively. The mean D2 was 352.0 (26.5-935.8), 146.4 (27.3-226.7), 90.7 (3.6-255.0), 42.2 (4.8-82.7), 88.0 (15.4-248.5), and 273.5 (98.3-611.6) mGy, respectively. The D2 of the skin dose was found to increase as the gating efficiency decreased.

CONCLUSIONS

The additional dose to the PTV was at most 1.9% of the prescribed dose over the course of treatment for real-time tumour monitoring. For OARs, we could confirm the high dose region, which may not be susceptible to radiation toxicity. However, to reduce the skin dose from SyncTraX, it is necessary to increase the gating efficiency.

Assessment of female breast dose for thoracic cone-beam CT using MOSFET dosimeters

Objective: To assess the breast dose during a routine thoracic cone-beam CT (CBCT) check with the efforts to explore the possible dose reduction strategy.

Materials and Methods: Metal oxide semiconductor field-effect transistor (MOSFET) dosimeters were used to measure breast surface doses during a thorax kV CBCT scan in an anthropomorphic phantom. Breast doses for different scanning protocols and breast sizes were compared. Dose reduction was attempted by using partial arc CBCT scan with bowtie filter. The impact of this dose reduction strategy on image registration accuracy was investigated.

Results: The average breast surface doses were 20.02 mGy and 11.65 mGy for thoracic CBCT without filtration and with filtration, respectively. This indicates a dose reduction of 41.8% by use of bowtie filter. It was found 220° partial arc scanning significantly reduced the dose to contralateral breast (44.4% lower than ipsilateral breast), while the image registration accuracy was not compromised.

Conclusions: Breast dose reduction can be achieved by using ipsilateral 220° partial arc scan with bowtie filter. This strategy also provides sufficient image quality for thorax image registration in daily patient positioning verification.